

Giuseppe Alberto Palumbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8071512/publications.pdf>

Version: 2024-02-01

210
papers

5,207
citations

94269

37
h-index

114278

63
g-index

216
all docs

216
docs citations

216
times ranked

6922
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). <i>Leukemia and Lymphoma</i> , 2022, 63, 189-198.	0.6	3
2	CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment. <i>Oncogenesis</i> , 2022, 11, 6.	2.1	19
3	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-OL study. <i>British Journal of Haematology</i> , 2022, 197, 190-200.	1.2	7
4	Immunological Subsets Characterization in Newly Diagnosed Relapsing/Remitting Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 819136.	2.2	5
5	Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection. <i>Cancers</i> , 2022, 14, 1173.	1.7	4
6	Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases. <i>Hematology Reports</i> , 2022, 14, 67-72.	0.3	4
7	Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Medicine</i> , 2022, 11, 1665.	1.0	2
8	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis. <i>Cancer</i> , 2022, 128, 2449-2454.	2.0	7
9	TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment. <i>Antioxidants</i> , 2022, 11, 767.	2.2	9
10	IGFBP-6: At the Crossroads of Immunity, Tissue Repair and Fibrosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4358.	1.8	13
11	Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. <i>Cancers</i> , 2022, 14, 2186.	1.7	5
12	In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection. <i>Scientific Reports</i> , 2022, 12, 7237.	1.6	2
13	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. <i>Current Oncology</i> , 2022, 29, 4970-4980.	0.9	2
14	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021, 193, 356-368.	1.2	19
15	Focus on Osteosclerotic Progression in Primary Myelofibrosis. <i>Biomolecules</i> , 2021, 11, 122.	1.8	8
16	Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 486.	1.8	10
17	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021, 11, 4.	2.8	41
18	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021, 39, 409-418.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. <i>Frontiers in Oncology</i> , 2021, 11, 643490.	1.3	12
20	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021, 127, 2657-2665.	2.0	14
21	Hemophagocytic Syndrome in a Patient with ALL: Morphology Still Matters. <i>Hemato</i> , 2021, 2, 347-352.	0.2	0
22	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	2.4	11
23	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
24	The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large B-cell lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e03817.	0.2	2
25	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021, 11, 752192.	1.3	7
26	Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. <i>American Journal of Blood Research</i> , 2021, 11, 417-426.	0.6	0
27	CXCL12/CXCR4 Axis Drives Mitochondrial Trafficking in Tumor Myeloma Microenvironment. <i>Blood</i> , 2021, 138, 2663-2663.	0.6	0
28	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Polycythemia Vera Resistant/Intolerant to Hydroxyurea. <i>Blood</i> , 2021, 138, 2581-2581.	0.6	1
29	IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis. <i>Aging</i> , 2021, 13, 25055-25071.	1.4	21
30	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	2.0	106
31	Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib. <i>Redox Biology</i> , 2020, 36, 101611.	3.9	30
32	Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells. <i>Cancers</i> , 2020, 12, 1999.	1.7	25
33	The Role of Inflammation and Inflammasome in Myeloproliferative Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 2334.	1.0	22
34	SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. <i>HemaSphere</i> , 2020, 4, e483.	1.2	7
35	Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview. <i>Frontiers in Oncology</i> , 2020, 10, 604143.	1.3	32
36	Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells. <i>Biomolecules</i> , 2020, 10, 696.	1.8	39

#	ARTICLE	IF	CITATIONS
37	Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3900.	1.8	12
38	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-world practice. <i>Annals of Hematology</i> , 2020, 99, 65-72.	0.8	13
39	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	0.7	2
40	Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. <i>British Journal of Haematology</i> , 2020, 189, 888-903.	1.2	61
41	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	3.3	14
42	Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells. <i>Cancers</i> , 2020, 12, 323.	1.7	22
43	Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. <i>Lancet Haematology</i> , 2020, 7, e456-e468.	2.2	244
44	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380.	0.8	15
45	Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2926.	1.8	8
46	Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study. <i>Blood</i> , 2020, 136, 37-38.	0.6	16
47	Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3622.	1.8	45
48	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.	0.6	2
49	Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients. <i>Blood</i> , 2020, 136, 26-26.	0.6	0
50	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020, 136, 17-18.	0.6	1
51	The Heme Oxygenase-1/Carbon Monoxide Pathway Activates TLR4 Signaling Promoting Bortezomib Resistance in Multiple Myeloma Cells. <i>Blood</i> , 2020, 136, 13-14.	0.6	0
52	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020, 136, 49-50.	0.6	0
53	First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
54	Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3548.	1.8	19

#	ARTICLE	IF	CITATIONS
55	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5459.	1.8	17
56	Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome. <i>Clinical Epigenetics</i> , 2019, 11, 121.	1.8	21
57	Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. <i>Frontiers in Oncology</i> , 2019, 9, 699.	1.3	43
58	TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. <i>Cell Death and Disease</i> , 2019, 10, 704.	2.7	36
59	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. <i>Cells</i> , 2019, 8, 1114.	1.8	40
60	Î±-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload. <i>International Journal of Molecular Sciences</i> , 2019, 20, 609.	1.8	37
61	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	0.8	3
62	The Role of New Technologies in Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2019, 9, 321.	1.3	37
63	Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 468-479.	1.2	17
64	Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. <i>Frontiers in Oncology</i> , 2019, 9, 57.	1.3	22
65	TLR4 signaling drives mesenchymal stromal cells (MSC) commitment to promote tumor microenvironment transformation in multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e90-e91.	0.2	0
66	Ixazomib inhibits osteoclastogenesis and promotes osteogenic differentiation in vitro. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195.	0.2	0
67	Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib. <i>Frontiers in Oncology</i> , 2019, 9, 1186.	1.3	142
68	Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019, 34, 16-25.	2.8	15
69	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	0.8	10
70	Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial. <i>Blood</i> , 2019, 134, 3000-3000.	0.6	7
71	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. <i>Blood</i> , 2019, 134, 839-839.	0.6	2
72	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18220-e18220.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019, 134, 4166-4166.	0.6	0
74	Inhibition of TLR4 Signaling Affects Mitochondrial Fitness Overcoming Bortezomib Resistance in Myeloma Plasma Cells. <i>Blood</i> , 2019, 134, 3073-3073.	0.6	0
75	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4188-4188.	0.6	0
76	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4184-4184.	0.6	1
77	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019, 134, 4174-4174.	0.6	2
78	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. <i>Blood</i> , 2019, 134, 4179-4179.	0.6	1
79	Ixazomib Modulates Bone Remodeling and Activates Sonic Hedgehog Pathways. <i>Blood</i> , 2019, 134, 4345-4345.	0.6	0
80	Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: a single-centre cohort pilot study. <i>Blood Transfusion</i> , 2019, 17, 196-199.	0.3	0
81	Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 1070-1080.	1.6	36
82	Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment. <i>Annals of Hematology</i> , 2018, 97, 745-754.	0.8	11
83	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian “Back to Life”™ project. <i>Quality of Life Research</i> , 2018, 27, 1545-1554.	1.5	9
84	Iron toxicity “Its effect on the bone marrow. <i>Blood Reviews</i> , 2018, 32, 473-479.	2.8	46
85	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	0.8	46
86	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. <i>Annals of Hematology</i> , 2018, 97, 1009-1018.	0.8	44
87	PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 675-683.	1.5	61
88	Comparison of <i>JAK2</i> ^{V617F} positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology. <i>Hematological Oncology</i> , 2018, 36, 269-275.	0.8	11
89	Efficacy and safety of ruxolitinib in intermediate-IPSS risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	0.8	29
90	Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. <i>Leukemia and Lymphoma</i> , 2018, 59, 423-433.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	2.0	31
92	Tryptophan Shortage Due to IDO-1 Expressed by High-Density Neutrophils Induce Immune-Suppression and Plasma Cell Fitness in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S246.	0.2	0
93	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.4	23
94	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	1.2	7
95	The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2018, 182, 701-704.	1.2	22
96	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	1.8	24
97	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	0.6	1
98	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	0.6	11
99	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. <i>Blood</i> , 2018, 132, 4511-4511.	0.6	8
100	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018, 132, 3052-3052.	0.6	0
101	Real-World Management of Myelofibrosis with Ruxolitinib: Initial Analysis of an Italian Observational Study (ROMEI). <i>Blood</i> , 2018, 132, 4312-4312.	0.6	0
102	Role of TLR4 in the Activation of a Pro-Tumor Phenotype of Mesenchymal Stromal Cells in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1892-1892.	0.6	0
103	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018, 132, 4303-4303.	0.6	3
104	Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. <i>Lancet Haematology</i> , 2017, 4, e127-e136.	2.2	132
105	The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. <i>Blood Cancer Journal</i> , 2017, 7, 649.	2.8	37
106	Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacytidine in High-Risk Myelodysplasia. <i>Frontiers in Pharmacology</i> , 2017, 8, 204.	1.6	19
107	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017, 8, 79073-79086.	0.8	63
108	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). <i>Oncotarget</i> , 2016, 7, 85764-85775.	0.8	80

#	ARTICLE	IF	CITATIONS
109	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2016, 11, e0158392.	1.1	30
110	Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome. Journal of Clinical Apheresis, 2016, 31, 443-447.	0.7	0
111	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. Blood, 2016, 128, 1128-1128.	0.6	4
112	Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233). Blood, 2016, 128, 3107-3107.	0.6	3
113	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. Blood, 2016, 128, 4251-4251.	0.6	2
114	Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. Blood, 2016, 128, 1242-1242.	0.6	0
115	Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Medicine, 2015, 4, 1789-1797.	1.3	18
116	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica, 2015, 100, 517-524.	1.7	6
117	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncology, The, 2015, 16, 1506-1514.	5.1	76
118	Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes. Leukemia Research, 2015, 39, 859-865.	0.4	17
119	Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. British Journal of Haematology, 2015, 168, 689-700.	1.2	76
120	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. British Journal of Haematology, 2015, 168, 361-370.	1.2	59
121	Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib. Blood, 2015, 126, 2767-2767.	0.6	3
122	Safety and Efficacy of Ruxolitinib in an 1869-Patient Cohort of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis. Blood, 2015, 126, 2799-2799.	0.6	6
123	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. Blood, 2015, 126, 91-91.	0.6	7
124	Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. Turkish Journal of Haematology, 2015, 32, 206-212.	0.2	4
125	JAK2V617F-Positive Patients with Essential Thrombocythemia or Early Primary Myelofibrosis: The Impact of Histological Diagnosis on Outcome. Blood, 2015, 126, 1614-1614.	0.6	0
126	Mesenchymal STEM CELLS Favor Tumor Growth By Generating Granulocyte-like Myeloid Derived Suppressor CELLS in CML Patients. Blood, 2015, 126, 4018-4018.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity Together with Polymorphonuclear Leukocytes (PMNs) in Chronic Myeloid Leukemia Patients. PLoS ONE, 2014, 9, e101848.	1.1	71
128	Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up. World Journal of Gastroenterology, 2014, 20, 12993.	1.4	49
129	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. European Journal of Haematology, 2014, 93, 207-213.	1.1	12
130	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. Clinical Cancer Research, 2014, 20, 6398-6405.	3.2	94
131	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leukemia Research, 2014, 38, 57-64.	0.4	68
132	Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Experimental Hematology, 2014, 42, 126-136.e1.	0.2	23
133	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. BMC Cancer, 2013, 13, 60.	1.1	15
134	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Annals of Hematology, 2013, 92, 25-32.	0.8	23
135	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leukemia and Lymphoma, 2013, 54, 2458-2465.	0.6	29
136	Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. Annals of Oncology, 2013, 24, 1038-1044.	0.6	10
137	Nuclear Translocation of Heme Oxygenase-1 Confers Resistance to Imatinib in Chronic Myeloid Leukemia Cells. Current Pharmaceutical Design, 2013, 19, 2765-2770.	0.9	80
138	Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive. Blood, 2013, 122, 3138-3138.	0.6	20
139	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. Blood, 2013, 122, 2711-2711.	0.6	0
140	Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma. Blood, 2013, 122, 4238-4238.	0.6	1
141	Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation. Bone Marrow Transplantation, 2012, 47, 24-32.	1.3	8
142	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. Journal of Hematology and Oncology, 2012, 5, 53.	6.9	9
143	Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up. Hematological Oncology, 2012, 30, 180-185.	0.8	11
144	Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. Hematological Oncology, 2012, 30, 27-33.	0.8	26

#	ARTICLE	IF	CITATIONS
145	Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells. <i>Blood</i> , 2012, 120, 5005-5005.	0.6	1
146	Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS). <i>Blood</i> , 2012, 120, 923-923.	0.6	10
147	Myeloid-Derived Suppressor Cells Increase in Chronic Myeloid Leukemia and Exert Immune Suppressive Activity.. <i>Blood</i> , 2012, 120, 2779-2779.	0.6	0
148	Myeloid Impairment Contributes to Immunoparesis in Multiple Myeloma but Not MGUS. <i>Blood</i> , 2012, 120, 1831-1831.	0.6	5
149	Patient-Reported Fatigue, Functional Aspects and Quality of Life in Elderly Patients with High-Risk Myelodysplastic Syndromes. Evidence From a Large Prospective International Study.. <i>Blood</i> , 2012, 120, 3163-3163.	0.6	0
150	In Vitro and in Vivo Evidence of an Anti-Angiogenic Effect of Lenalidomide in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 1782-1782.	0.6	2
151	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. <i>European Journal of Haematology</i> , 2011, 86, 216-225.	1.1	6
152	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	1.5	67
153	BRIT1/MCPH1 Expression in Chronic Myeloid Leukemia and Its Regulation of the G2/M Checkpoint. <i>Acta Haematologica</i> , 2011, 126, 205-210.	0.7	34
154	A Prospective, Multi Center Phase II Study Evaluating Predictive Factors for Lenalidomide Treatment in Relapse or Refractory Chronic Lymphocytic Leukemia Patients (LE.P.RE.): Preliminary Results about the First 20 Enrolled Patients. <i>Blood</i> , 2011, 118, 1782-1782.	0.6	0
155	Heme Oxygenase 1-Induced Resistance to Imatinib In Chronic Myelogenous Leukemia Cells. <i>Blood</i> , 2011, 118, 4410-4410.	0.6	0
156	Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,. <i>Blood</i> , 2011, 118, 3818-3818.	0.6	4
157	Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 276-288.	1.3	94
158	Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 110-120.	1.0	21
159	Broad copy neutral loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype acute myeloid leukemia genomes. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 1014-1023.	1.5	28
160	Azacitidine for the treatment of lower risk myelodysplastic syndromes. <i>Cancer</i> , 2010, 116, 1485-1494.	2.0	98
161	Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. <i>Leukemia Research</i> , 2010, 34, 1539-1542.	0.4	31
162	Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma. <i>Acta Haematologica</i> , 2010, 123, 91-95.	0.7	17

#	ARTICLE	IF	CITATIONS
163	Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 3882-3882.	0.6	0
164	ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. <i>Anticancer Research</i> , 2010, 30, 4525-35.	0.5	6
165	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. <i>Journal of Immunology</i> , 2009, 182, 4415-4422.	0.4	227
166	Effects of imatinib mesylate in osteoblastogenesis. <i>Experimental Hematology</i> , 2009, 37, 461-468.	0.2	41
167	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. <i>BMC Medical Genomics</i> , 2009, 2, 20.	0.7	20
168	CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009, 33, 1212-1216.	0.4	124
169	Variation of T-Reg and CD 200+ T- Lymphocytes After in Vitro Treatment with Active Drugs against CLL.. <i>Blood</i> , 2009, 114, 1239-1239.	0.6	0
170	Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma.. <i>Blood</i> , 2009, 114, 3662-3662.	0.6	3
171	A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells. <i>Journal of Neuroscience Research</i> , 2008, 86, 1927-1935.	1.3	30
172	Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2008, 120, 19-30.	0.7	28
173	Role of New Tyrosine Kinase Inhibitors in Osteoblastogenesis. <i>Blood</i> , 2008, 112, 4751-4751.	0.6	0
174	The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FCÎ³R11a and FCÎ³R11a Polymorphisms. <i>Journal of Chemotherapy</i> , 2007, 19, 315-321.	0.7	17
175	Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma?. <i>Annals of Oncology</i> , 2007, 18, 351-356.	0.6	39
176	FcÎ³RIIIA and FcÎ³RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. <i>Haematologica</i> , 2007, 92, 1127-1130.	1.7	89
177	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2007, 110, 4672-4672.	0.6	1
178	Effect of Hypoxia on the Expression of BRIT1 in K562 Cell Line: Implication for Resistance to Imatinib.. <i>Blood</i> , 2007, 110, 4530-4530.	0.6	0
179	Role of Imatinib Mesylate in Osteoblastogenesis.. <i>Blood</i> , 2007, 110, 1928-1928.	0.6	1
180	Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamethasone in Previously Treated Myeloma Patients.. <i>Blood</i> , 2007, 110, 2728-2728.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.. Blood, 2007, 110, 4307-4307.	0.6	0
182	Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.. Blood, 2006, 108, 2507-2507.	0.6	1
183	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. Blood, 2006, 108, 4981-4981.	0.6	0
184	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. Blood, 2006, 108, 4387-4387.	0.6	0
185	Pyrrolidinedithiocarbamate Induces Apoptosis in Human Acute Myelogenous Leukemic Cells Affecting NF- κ B Activity. Cancer Investigation, 2005, 23, 404-412.	0.6	9
186	Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. European Journal of Haematology, 2004, 72, 45-51.	1.1	15
187	Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leukemia Research, 2004, 28, 367-372.	0.4	46
188	Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leukemia Research, 2004, 28, 469-477.	0.4	57
189	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. British Journal of Haematology, 2003, 120, 405-412.	1.2	27
190	Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. Bone Marrow Transplantation, 2003, 32, 57-63.	1.3	88
191	Emangioma, plasmocitoma e mieloma multiplo del rachide. The Neuroradiology Journal, 2002, 15, 445-450.	0.1	0
192	Alternation of Epirubicin and Mitoxantrone in CHOP-like Regimens Retains Efficacy and Reduces Overall Toxicity in Elderly Patients with High and Intermediate Grade Non-Hodgkin Lymphomas. Leukemia and Lymphoma, 2002, 43, 2319-2324.	0.6	6
193	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 116, 774-780.	1.2	35
194	Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia, 2001, 15, 976-980.	3.3	80
195	Angiogenesis in Chronic Myeloproliferative Diseases. Acta Haematologica, 2001, 106, 177-183.	0.7	59
196	Angiogenesis in acute myeloid leukemia. Blood, 2000, 96, 3656-3659.	0.6	16
197	In vitro Apoptotic Response of Freshly Isolated Chronic Myeloid Leukemia Cells to all-trans Retinoic Acid and Cytosine Arabinoside. Acta Haematologica, 2000, 104, 57-64.	0.7	3
198	Risk factors for genital prolapse in non-hysterectomized women around menopause. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2000, 93, 135-140.	0.5	94

#	ARTICLE	IF	CITATIONS
199	Angiogenesis in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3656-3659.	0.6	3
200	Mutation and Haplotype Studies of Familial Mediterranean Fever Reveal New Ancestral Relationships and Evidence for a High Carrier Frequency with Reduced Penetrance in the Ashkenazi Jewish Population. <i>American Journal of Human Genetics</i> , 1999, 64, 949-962.	2.6	280
201	Evaluation of taxol cytotoxicity on B-CLL cells in vitro. <i>Leukemia and Lymphoma</i> , 1997, 26, 115-119.	0.6	9
202	Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia. <i>Blood</i> , 1997, 90, 4918-4923.	0.6	36
203	Relationship between tumour necrosis factor α and sex steroid concentrations in the follicular fluid of women with immunological infertility. <i>Human Reproduction</i> , 1996, 11, 265-268.	0.4	29
204	In Vitro Sensitivity of B-CLL Cells to Fludarabine and Interferons. <i>Leukemia and Lymphoma</i> , 1995, 17, 449-453.	0.6	7
205	Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 93, 526-533.	1.5	30
206	A Physiological Role for the Neuropeptide Luteinizing Hormone-Releasing Hormone (LHRH) During the Maturation of Thymus Gland Function. <i>International Journal of Neuroscience</i> , 1990, 51, 287-289.	0.8	14
207	Neuroendocrine modulation of lymphocyte's activity during the physiological menstrual cycle. <i>Pharmacological Research</i> , 1990, 22, 101-102.	3.1	2
208	Peptidergic modulation of immune system development: Role of luteinizing hormone-releasing hormone. <i>Pharmacological Research</i> , 1990, 22, 97-98.	3.1	5
209	Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Restoration of Age-Associated Decline of Thymus Weight, Thymic LHRH Receptors, and Thymocyte Proliferative Capacity. <i>Endocrinology</i> , 1989, 125, 1037-1045.	1.4	133
210	Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0